Regeneron Pharmaceuticals Inc. added Tony Coles to its board.
The director was nominated by Sanofi, which owns 21.9% of the company, according to S&P Capital IQ data.
Coles is the chairman and CEO of Yumanity Therapeutics.
Sanofi nominates director to Regeneron Pharmaceuticals board
Climate Credit Analytics: Linking climate scenarios to financial impacts
Global M&A Infographic Q1 2021
Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge
COVID-19 Impact & Recovery: Private Equity
Sanofi nominates director to Regeneron Pharmaceuticals board
- Author Ephraim Bie
- Theme Healthcare & Pharmaceuticals